Lamivudine Tablets

Lamivudine Tablets (Lamivir-HBV and Lamivir) - Product Information

Lamivir-HBV Tablets (Lamivudine 100 mg )are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation.
Lamivir (Lamivudine 150 mg ) is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Lamivir-HBV and Lamivir manufactured by Cipla Limited, India, are available in the strengths of 100 mg and 150 mg Lamivudine.
We also have in stock Valclovir tablets (Generic Valacyclovir tablets) which is also used to treat herpes virus infections, including herpes labialis (also known as cold sores), herpes zoster (also known as shingles), and herpes simplex (also known as genital herpes) in adults.

Name of the Drug

Lamivir-HBV tablets and Lamivir tablets.

Manufacturer of Lamivir-HBV and Lamivir Tablets

Cipla Limited, India  
Website: www.cipla.com

Active Pharmaceutical Ingredient

The active ingredient present in Lamivir HBV and Lamivir tablets is Lamivudine. Each tablet of Lamivir HBV and Lamivir contains 100 mg or 150 mg of Lamivudine respectively.

Uses of Lamivir-HBV and Lamivir Tablets

Lamivir Tablets (Lamivudine 150 mg) is used in combination with other medicines for the treatment of the infection caused by the human immunodeficiency virus (HIV). HIV is the virus that causes acquired immune deficiency syndrome (AIDS).
Lamivudine will not cure or prevent HIV infection or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay the development of serious health problems usually related to AIDS or HIV disease from occurring. Lamivudine will not keep you from spreading HIV to other people. People who receive this medicine may continue to have other problems usually related to AIDS or HIV disease.
Lamivir HBV (Lamivudine 100 mg) is also used to treat chronic (long-term) hepatitis B virus (HBV) infection.

Lamivir-HBV and Lamivir Tablets - Dosage

Generic Lamivudine tablets should be administered exactly as suggested by your doctor. Your doctor may recommend a dosage of Lamivir HBV and Lamivir tablets depending on your age, medical requirement, body weight, other medical conditions, and current medications.
Lamivir Tablets: The recommended dosage of Lamivir in HIV-1 infected adults is 300 mg daily, administered as either 150 mg taken orally twice daily, or 300 mg taken orally once daily with or without food.
If Lamivudine is administered to a patient infected with HIV-1 and HBV, the dosage indicated for HIV-1 therapy should be used as part of an appropriate combination regimen Dosing of Lamivir is adjusted in accordance with renal function.
Lamivir-HBV Tablets: The recommended oral dose of Lamivir-HBV Tablets in adults is 100 mg once daily. Lamivir-HBV Tablets has not been evaluated in pediatric patients. For patients with Renal Impairment, it is recommended that doses of lamivudine be adjusted.
Lamivir HBV and Lamivir tablets work effectively if the amount of Lamivudine is maintained at a constant level in the body. You should be systematic about the daily schedule for the medication such that you take tablets at about the same time every day, to get the maximum benefit of the medication. Continue taking Lamivir HBV and Lamivir tablets without missing any doses for the recommended treatment period and do not stop the treatment suddenly even if you feel better.

Please consult your doctor for exact dosing instructions. Lamivir HBV and Lamivir tablets (Generic Lamivudine tablets) should be administered in the dose prescribed by the doctor and for the duration recommended by the doctor.

Missed Dose

If you forget to take your regular tablet dose on time, take it whenever you remember.
If you remember the next day, skip the missed dose and take your scheduled dose. Do not take a double dose to compensate the missed dose.

Mechanism of Action

Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that works by interfering with the replication of HIV and HBV (Hepatitis B virus).
It is converted into its active form, lamivudine triphosphate (3TC-TP), inside cells. This metabolite then acts as a chain terminator during DNA synthesis, preventing the virus from replicating.

Storage Instructions for Lamivir-HBV and Lamivir Tablets

Store Lamivir-HBV and Lamivir Tablets at controlled room temperature (20°C to 25°C),protected from heat, moisture, and sunlight. Excursions are permitted from 15°C to 30°C.
Retain the original packing of the medication and do not consume past its expiration date printed on the blister pack. Keep the pack of Lamivir-HBV and Lamivir Tablets away from the reach of children and pets. Do not dispose the tablets along with domestic waste or sewage. Consult your doctor or pharmacist about the correct method of disposal.

Contraindications

Lamivir HBV and Lamivir tablets are contraindicated in patients with a hypersensitivity to Lamivudine or any inactive ingredient present in tablets. are contraindicated in the following cases:

Overdose

There is no known specific treatment for overdose with EPIVIR. If overdose occurs, the patient should be monitored and standard supportive treatment applied as required. Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event

Warnings and Precautions

• Co-infected HIV-1/HBV Patients: Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported.
• Hepatic decompensation, some fatal, has occurred in HIV-1/HCV co-infected patients receiving interferon and ribavirin-based regimens. Monitor for treatment-associated toxicities. Discontinue Lamivudine as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both.
• Pancreatitis: Use with caution in pediatric patients with a history of pancreatitis or other significant risk factors for pancreatitis. Treatment with lamivudine should be stopped immediately if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur.
• Immune reconstitution syndrome and redistribution/accumulation of body fat have been reported in patients treated with combination antiretroviral therapy.
• Lower virologic suppression rates and increased risk of viral resistance were observed in pediatric subjects who received lamivudine oral solution concomitantly with other antiretroviral oral solutions compared with those who received tablets.
• Effects on Ability to Drive and Use Machines:No studies on the effects on the ability to drive and use machines have been performed. However, individuals should be informed that dizziness has been reported during treatment with lamivudine.

Lamivudine Side Effects

The most common reported Lamivudine side effects with an incidence greater than or equal to 15% in adults were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough.
The most common reported Lamivudine side effects with an incidence greater than or equal to 15% in pediatric subjects were fever and cough.

Lamivudine Tablets (Lamivir-HBV and Lamivir) During Pregnancy

Lamivudine tablets (Lamivir-HBV and Lamivir) has been classified by the US FDA as Pregnancy Category C.
Available data from the Antiretroviral Pregnancy Registry show no difference in the risk of overall major birth defects for lamivudine compared with the background rate for major birth defects of 2.7% in the US reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) reference population.
Do not use this medicine without your doctor's consent in case you are pregnant. Stop using this medication and inform your doctor immediately if you become pregnant during treatment.

Nursing Considerations

HIV-1-infected mothers should not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection. Because of the potential for HIV-1 transmission mothers should be instructed not to breastfeed.
Do not breast-feed a baby if you are using Lamivudine Tablets (Lamivir-HBV and Lamivir) .

Buy Lamivudine Pills Online From Only $0.56 per Pill

You can buy Generic Lamivudine-HBV and Generic Lamivudine online from Everest Online Pharmacy at a cheap price. Lamivir-HBV 100 mg and Lamivir 150 mg pills, manufactured by Cipla Limited, India are supplied in a blister strip of 10 tablets. The 100 mg Lamivudine HBV tablets as well as the 150 mg Lamivudine tablets cost only $0.56 per unit when you place an order for 360 tablets.

Disclaimer

The above information is provided to the best of our knowledge and in good faith. It is without a warrant of any kind, expressed or implied.

Shipping Restriction